Clinical Background
The reported number of rubella cases in the U.S. over the last 5 years is low enough for the Centers for Disease Control (CDC) to state that the endemic disease has been eliminated.
Epidemiology
- Incidence – <25 cases a year in the U.S.
- Age – usually young children who are unvaccinated
- Transmission
- Via droplets, aerosol particles – close contact required
Organism
- Rubella, an RNA virus, is the only member of the Togaviridae family
- Virus infects cells in the upper respiratory tract and replicates in the lymphoid system
- The virus then spreads to other organs
Clinical Presentation
- Transmission can occur up to 7 days before and 7 days after onset of the rash
- In children and adults, infection usually results in mild, exanthematous disease
- Adults are more likely to experience prodromal phase – fever, headache, sore throat, cough, conjunctivitis
- Rare complications include arthralgias and arthritis, thrombocytopenia, hemorrhage and encephalitis
- In pregnant women, particularly during first trimester, infection can result in fetal death or congenital abnormalities
- The spectrum of congenital defects called TORCH syndrome occurs with maternal exposure to rubella (also to Toxoplasma gondii, cytomegalovirus and herpes simplex virus)
Click here for WHO case definition for congenital rubella syndrome
| WHO Case Definition for Congenital Rubella Syndrome (CRS) |
- Suspected case
- Any infant less than 1 year of age in whom a health worker suspects CRS
- A health worker should suspect CRS when an infant presents with heart disease and/or suspicion of deafness and/or one or more of the following eye signs: white pupil (cataract), diminished vision, pendular movement of the eyes (nystagmus), squint, smaller eye ball (microphthalmos), or larger eye ball (congenital glaucoma)
- When an infant’s mother has a history of suspected or confirmed rubella during pregnancy, even when the infant shows no signs of CRS
- Clinically confirmed CRS case
- An infant in whom a qualified physician detects two of the complications in section A or one from section A and one from section B:
- Section A: cataracts, congenital glaucoma, congenital heart disease, hearing impairment, pigmentary retinopathy
- Section B: purpura, splenomegaly, microcephaly, mental retardation, meningoencephalitis, radiolucent bone disease, jaundice with onset within 24 h after birth
- Laboratory-confirmed CRS case – an infant with rubella IgM antibody who has clinically confirmed CRS
- Congenital rubella infection – an infant with rubella IgM antibody who does not have clinically confirmed CRS
|
- Disease can be asymptomatic
- Congenital abnormalities include:
- Eye defects – cataracts, glaucoma, iris hypoplasia, retinopathy
- Sensorineural or central deafness
- Congenital heart disease (patent ductus arteriosus, pulmonary stenosis, pulmonary arterial hypoplasias)
- Central nervous system – mental retardation with central nervous system calcifications, microcephaly
- 10-20% of newborns infected in utero will die during the first year of life
- Because complications in utero are so severe, diagnosis during first trimester may result in decision to terminate pregnancy
Treatment
- Treatment is supportive and symptom based
Prevention
- Vaccination programs have resulted in marked decrease in infections
- Estimated >95% of children in U.S. are vaccinated
- Vaccine is live, attenuated virus and contraindicated in pregnant women
Diagnosis
- Indications for testing – prenatal screening for presence of maternal antibodies, typical rash in unvaccinated patient
- Laboratory testing
- Antibody testing
- In primary rubella infection, the appearance of clinical symptoms is associated with the appearance of both IgG and IgM antibodies
- IgM antibodies – detectable a few days after onset of symptoms; peak 7-10 days later
- Prenatal screening – test women prior to pregnancy to confirm presence of IgG antibodies
Differential Diagnosis
- Measles
- Parvovirus B19
- Human herpesvirus 6 (HHV6)
- West Nile virus
- Enterovirus
- Dengue fever virus
Pharmacogenetics and Therapeutic Drug Monitoring
Indications for Laboratory Testing
- Tests generally appear in the order most useful for common clinical situations
- Click on number for test-specific information in the ARUP Laboratory Test Directory
| Test Name and Number |
Recommended Use |
Limitations |
Follow Up |
| Rubella Antibodies, IgG & IgM 0050552 Method: Chemiluminescent Immunoassay |
Determine rubella immune status in women of child-bearing age, in pregnant women and in individuals who may have close contact with pregnant women, such as hospital personnel and preschool children Diagnose rubella infection during 1st trimester of pregnancy |
|
If test results are equivocal, repeat testing in 10-14 days |
Additional Tests Available
Click the plus sign to expand the table of additional tests.
| Test Name and Number | Comments |
| Rubella Antibody, IgG 0050771 Method: Chemiluminescent Immunoassay |
|
| Rubella Antibody, IgM 0050551 Method: Chemiluminescent Immunoassay |
|
| TORCH Antibodies, IgG 0050772 Method: Chemiluminescent Immunoassay |
|
| TORCH Antibodies, IgM 0050665 Method: Refer to individual components |
|
Guidelines
General References
References from the ARUP Institute for Clinical and Experimental Pathology®
Comprehensive Review: September 2009
Last Update: August 2009